Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment
Abstract Objective The objective of this study was to identify serum complement factor-based biomarkers indicative of clinical efficacy in patients with first-episode schizophrenia (SCZ) following treatment with aripiprazole. Methods The retrospective study cohort comprised 40 patients diagnosed wit...
Saved in:
| Main Authors: | Yin Cao, Jun Liang, Biao Dai, Feng Shan, Qingrong Xia |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Psychiatry |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12888-024-06437-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A randomized trial of aripiprazole vs blonanserin for the treatment of acute schizophrenia and related disorders
by: Kishi T, et al.
Published: (2016-11-01) -
Comparative effectiveness of aripiprazole and olanzapine on neurocognitive profile of patients with schizophrenia
by: Sanya Sharma, et al.
Published: (2023-10-01) -
Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients
by: Zhen Mao, et al.
Published: (2024-12-01) -
Dynamics of mental state and prolactin levels in patients with chronic schizophrenia during aripiprazole therapy
by: L. N. Gorobets, et al.
Published: (2023-10-01) -
Comparative cardiovascular outcomes of aripiprazole vs. risperidone in patients with type 2 diabetes and schizophrenia: a retrospective cohort study
by: Yi-Ting Yeh, et al.
Published: (2025-07-01)